<DOC>
	<DOCNO>NCT01099332</DOCNO>
	<brief_summary>This trial aim test hypothesis 1 ) single dose zinc cysteine proprietary gastro-retentive form produce sustain blood level zinc give large bioavailable amount zinc FDA approve preparation inorganic zinc acetate ; 2 ) zinc cysteine gastro-retentive , sustained-release preparation well tolerate significantly less gastrointestinal side effect zinc acetate capsule . The trial also test hypothesis , 6 month daily administration , zinc cysteine subject show reduced serum non-ceruloplasmin copper . Additionally , subject perform test mental function , include dementia rating scale , Mini Mental Status Examination ADAS-cognitive performance test aim Alzheimer 's status assessment . Tests administer baseline , 3 6 month , performance result compare . Care-giver assessment also note .</brief_summary>
	<brief_title>Trial Novel Oral Zinc Cysteine Preparation Alzheimer 's Disease</brief_title>
	<detailed_description>This multi-center study aim determine pharmacokinetics pharmacodynamics novel gastro-retentive , sustained-release zinc cysteine preparation blood urine measure copper zinc balance Alzheimer 's disease mild cognitive impairment . Data expect derived include tolerability novel preparation comparison oral inorganic zinc salt , long-term effect primarily blood-measured copper-zinc balance . The study design prospective , randomize , double blind placebo-controlled clinical trial , duration individual subject 6 month . The study perform total 3 site , direction single principal investigator , sub-investigator . The statistical plan call comparison data two long-term parallel group use ANOVA applicable technique . In addition blood parameter , mental function assessment obtain baseline , 3 6 month evaluate statistically .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<criteria>Alzheimer 's disease mild moderate diagnose standard clinical , functional NINDAADRDA criterion Mild cognitive impairment diagnose standard clinical , functional NINDAADRDA criterion All subject able swallow Tablets Subjects take copper zinc contain supplement must 30day wash start study material Screening laboratory value either within normal limit deem clinically significant investigator Subjects study companions/care giver unable give adequate inform consent Presence disease condition know affect biometal homeostasis Presence psychosis , substance abuse major medical neurological issue Presence vascular dementia Clinically significant anemia time screen visit Current use decoppering drug trientine penicillamine</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Copper metabolism</keyword>
	<keyword>Zinc metabolism</keyword>
	<keyword>Ceruloplasmin</keyword>
</DOC>